These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 28619281)
1. Metabolism of KO143, an ABCG2 inhibitor. Liu K; Zhu J; Huang Y; Li C; Lu J; Sachar M; Li S; Ma X Drug Metab Pharmacokinet; 2017 Aug; 32(4):193-200. PubMed ID: 28619281 [TBL] [Abstract][Full Text] [Related]
2. Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance. Cai CY; Zhai H; Lei ZN; Tan CP; Chen BL; Du ZY; Wang JQ; Zhang YK; Wang YJ; Gupta P; Wang B; Chen ZS Eur J Med Chem; 2019 Oct; 179():849-862. PubMed ID: 31302589 [TBL] [Abstract][Full Text] [Related]
3. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells. Sabnis NG; Miller A; Titus MA; Huss WJ Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956 [TBL] [Abstract][Full Text] [Related]
4. Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP). Liao M; Chuang BC; Zhu Q; Li Y; Guan E; Yu S; Yang J; Prakash S; Xia CQ Xenobiotica; 2018 May; 48(5):467-477. PubMed ID: 28485193 [TBL] [Abstract][Full Text] [Related]
5. Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors. Zhu J; Lei S; Lu J; Hao Y; Qian Q; Devanathan AS; Feng Z; Xie XQ; Wipf P; Ma X Eur J Med Chem; 2023 Nov; 259():115666. PubMed ID: 37482017 [TBL] [Abstract][Full Text] [Related]
6. Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice. Mairinger S; Zoufal V; Wanek T; Traxl A; Filip T; Sauberer M; Stanek J; Kuntner C; Pahnke J; Müller M; Langer O Eur J Pharm Sci; 2018 Mar; 115():212-222. PubMed ID: 29360507 [TBL] [Abstract][Full Text] [Related]
7. The Inhibitor Ko143 Is Not Specific for ABCG2. Weidner LD; Zoghbi SS; Lu S; Shukla S; Ambudkar SV; Pike VW; Mulder J; Gottesman MM; Innis RB; Hall MD J Pharmacol Exp Ther; 2015 Sep; 354(3):384-93. PubMed ID: 26148857 [TBL] [Abstract][Full Text] [Related]
8. Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles. Li Y; Woo J; Chmielecki J; Xia CQ; Liao M; Chuang BC; Yang JJ; Guan MY; Plesescu M; Prakash SR Bioorg Med Chem Lett; 2016 Jan; 26(2):551-555. PubMed ID: 26642765 [TBL] [Abstract][Full Text] [Related]
9. ABCG2-mediated suppression of chlorin e6 accumulation and photodynamic therapy efficiency in glioblastoma cell lines can be reversed by KO143. Abdel Gaber SA; Müller P; Zimmermann W; Hüttenberger D; Wittig R; Abdel Kader MH; Stepp H J Photochem Photobiol B; 2018 Jan; 178():182-191. PubMed ID: 29156346 [TBL] [Abstract][Full Text] [Related]
10. Role of ABCG2 in transport of the mammalian lignan enterolactone and its secretion into milk in Abcg2 knockout mice. Miguel V; Otero JA; García-Villalba R; Tomás-Barberán F; Espín JC; Merino G; Álvarez AI Drug Metab Dispos; 2014 May; 42(5):943-6. PubMed ID: 24568887 [TBL] [Abstract][Full Text] [Related]
11. Toxicokinetics of the food-toxin IQ in human placental perfusion is not affected by ABCG2 or xenobiotic metabolism. Immonen E; Kummu M; Petsalo A; Pihlaja T; Mathiesen L; Nielsen JK; Knudsen LE; Vähäkangas K; Myllynen P Placenta; 2010 Jul; 31(7):641-8. PubMed ID: 20570348 [TBL] [Abstract][Full Text] [Related]
12. Structure of the Human Cholesterol Transporter ABCG1. Skarda L; Kowal J; Locher KP J Mol Biol; 2021 Oct; 433(21):167218. PubMed ID: 34461069 [TBL] [Abstract][Full Text] [Related]
13. Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection. Zander SA; Beijnen JH; van Tellingen O J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():129-36. PubMed ID: 23291288 [TBL] [Abstract][Full Text] [Related]
14. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP). González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460 [TBL] [Abstract][Full Text] [Related]
15. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2). Römermann K; Helmer R; Löscher W Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2). Krapf MK; Gallus J; Wiese M Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513 [TBL] [Abstract][Full Text] [Related]
17. Sulfonation of raloxifene in HEK293 cells overexpressing SULT1A3: Involvement of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in excretion of sulfate metabolites. Zhou X; Wang S; Sun H; Wu B Drug Metab Pharmacokinet; 2015 Dec; 30(6):425-33. PubMed ID: 26611713 [TBL] [Abstract][Full Text] [Related]
18. Total hepatocellular disposition profiling of rosuvastatin and pitavastatin in sandwich-cultured human hepatocytes. Kanda K; Takahashi R; Yoshikado T; Sugiyama Y Drug Metab Pharmacokinet; 2018 Jun; 33(3):164-172. PubMed ID: 29724614 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2). Spindler A; Stefan K; Wiese M J Med Chem; 2016 Jul; 59(13):6121-35. PubMed ID: 27280693 [TBL] [Abstract][Full Text] [Related]
20. Structural basis of small-molecule inhibition of human multidrug transporter ABCG2. Jackson SM; Manolaridis I; Kowal J; Zechner M; Taylor NMI; Bause M; Bauer S; Bartholomaeus R; Bernhardt G; Koenig B; Buschauer A; Stahlberg H; Altmann KH; Locher KP Nat Struct Mol Biol; 2018 Apr; 25(4):333-340. PubMed ID: 29610494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]